Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity
Genetically attenuated malaria parasites with extended liver-stage arrest (GA2) showed 89% protection in a clinical trial, surpassing earlier vaccine candidates...
A new malaria vaccine achieves an unparalleled 89% efficacy by targeting late-liver-stage antigens, unlocking new horizons in the fight against global disease.
...
Read More
Other Stories in Health
- New biosensor technology could revolutionize mpox diagnosis
- Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes
- EU regulator backs Eisai-Biogen Alzheimer’s drug
- Stem-cell implants restore vision in patients with corneal stem cell deficiency
- Reducing In-Home Smoking: Practical Approaches for Primary Care Clinicians
- Johns Hopkins University MSN (Entry into Nursing) Spring 2025
- 7 benefits of eating a rainbow diet
- Study shows toddlers learn better from impossible events
- New model sheds light on APOE4's role in Alzheimer's pathology
.png)
